| Tmunity stops solid tumor CAR-T trial after 2 patients die After flops and setbacks, Auris Medical pivots to RNA with Trasir Therapeutics buyout VenBio raises $550M to back its next batch of biotech startups Bayer picks up radiotherapeutics biotech to prop up dwindling sales in prostate cancer program Vasopharm's brain injury drug fails to improve patient outcomes in phase 3 Stablix lands on stable footing with $63M series A for protein stabilization efforts With $189M freshly in the bank, Repertoire Immune Medicines nabs ex-Celgene exec as CMO Amyl raises $22M to target common element of protein aggregates Cognoa's AI app for diagnosing childhood autism gets FDA green light How a distinct type of tau protein could offer a new target for treating Alzheimer's disease German life science services co Proteros pens AstraZeneca cancer drug development pact Featured Story | By Nick Paul Taylor Tmunity Therapeutics has stopped development of its lead CAR-T therapy after two patients died of a form of neurotoxicity. The news, details of which were first reported by Endpoints, has implications for the broader push to establish cell therapies as treatments for solid tumors. read more |
| |
|---|
|
| | Webinar: Tenders for the Win - A Strategy to Secure Bids and Increase Revenue Thursday, June 17 | 10am ET / 7am PT Join our tender experts for a virtual session to learn strategies to optimize your bids, streamline processes, and improve collaboration and visibility across the tender lifecycle. You’ll also hear from Veronica Gil, Pricing & Tender Director, Baxter EMEA, on how her team leveraged technology to centralize processes and develop a winning tender strategy. Register Now. |
Top Stories By Ben Adams It’s all-change at Auris Medical as it ditches its leaking pipeline, changes it name and its ticker as it picks up an RNA biotech to try to keep going, but in a new guise. read more By Amirah Al Idrus VenBio banked about $550 million in its latest fund to invest in a dozen or so new life sciences companies as well as to support its portfolio companies in financings both private and public. As with its three predecessors, the firm will invest Fund IV primarily in companies “developing biopharmaceuticals for unmet medical needs.” read more By Annalee Armstrong Amid sliding sales for prostate cancer drug Xofigo, Bayer will bolster its portfolio of targeted alpha therapies with the acquisition of radiotherapeutics biotech Noria Therapeutics and subsidiary PSMA Therapeutics. The deal, of which financial details were not disclosed, will see Bayer pick up exclusive rights to two investigational therapies in prostate cancer that will complement the already approved therapy Xofigo, according to a release. read more By Kyle LaHucik Nearly 14 years after completing the first-in-human study, Vasopharm has hit another major snag with its lead candidate ronopterin, which has failed to improve the outcomes of patients with traumatic brain injuries after six months in a late-stage trial. The company is now going to take a step back and re-evaluate further regulatory options for the therapy. read more By Kyle LaHucik Stablix Therapeutics launches today with a $63 million series A to bankroll work on protein stabilization in the hopes of treating rare diseases, cancer and immunological disorders. read more By Ben Adams Repertoire Immune Medicines has poached Theodore Reiss, M.D., as executive vice president and chief medical officer to help run its DECODE tech against cancer. read more By Nick Paul Taylor Amyl Therapeutics has raised €18.3 million ($22.3 million) to advance therapies against diseases driven by the buildup of amyloid. The cash equips Amyl to take drugs that target misfolded proteins linked to progressive peripheral and neurodegenerative rare diseases to preclinical proof of concept. read more By Conor Hale In a first for the use of artificial intelligence in healthcare, the FDA has given a green light to a program designed to help primary care doctors diagnose autism in children at an early age, potentially when interventions may have the greatest effect on their neurodevelopment. read more By Angus Liu A research team led by scientists at Harvard Medical School have identified a distinct type of tau protein called cis P-tau that drives degeneration of neurons. In mouse models, an antibody targeting the protein improved neurodegeneration and memory loss in mice, suggesting the approach might work in Alzheimer's. read more By Ben Adams As AstraZeneca continues to try and ramp up its cancer pipeline, it has hired Proteros biostructures to jointly discover and develop new small molecules for an array of oncology assets. read more Resources Sponsored by: Clinical Ink For faster deployment, improved patient engagement, and better-quality data — go where your patients are. GO BYOD with Lunexis™ from Clinical Ink. Sponsored by SDG Group Discover how Ashfield Healthcare uses the power of data and analytics to enable pre-call planning, inform sales rep actions and drive higher market share for its target pharmaceutical products. Sponsored by: BBK Worldwide Create a more diverse and inclusive clinical trial enrollment and engagement environment by learning the barriers to participation and the strategies to overcome them. Sponsored by: Thermo Fisher Scientific Autologous cell and gene therapy workflows involve isolating cells from an individual, engineering the cells, expanding and concentrating them, and infusing them back into the patient. Optimized automation of certain steps of the workflow may decrease hands-on time and the cost of the cell manufacturing process. Sponsored By: Veeva Learn how to develop a standards program that has your full team’s buy-in and improves the efficiency and quality of your clinical trials. Sponsored By: Veeva One top 10 pharma outlines three key steps to launching a modular content strategy to generate localized content faster. Sponsored By: Blue Matter This 77-page e-book explores 7 keys to success that any biopharma company needs to keep in mind as it enters Europe. Sponsored By: WCG Trifecta The new standards in study training help sponsors and CROs reduce costs by 60%, cut training time by 50%, and start enrollment 55 days faster – learn more today. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process intesification Sponsored By: August Bioservices How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond? Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Drug Development Boot Camp® 2021 Onsite and VIRTUAL in real time November 17-18, 2021 | Register now! Pre-Boot Camp preparation is now available. Vaccines, cell and gene therapy, antibodies, and RNA-based drugs June 10-11, 2021 | 9 a.m. EST / 6 a.m. PST Next Gen: What’s beyond the leading edge of biotech and pharma? June 22-23, 2021 | Virtual Event Biopharma Supply Chain June 29-30, 2021 | Virtual Event | 